Table 1.
Characteristics of participants at baseline*
| Characteristic | Celecoxib (n = 49) | Placebo (n =51) | Total (n = 100) | P value† |
|---|---|---|---|---|
| Demographic | ||||
| Median age, y (IQR) | 68 (49 to 87) | 66 (50 to 82) | 67 (49 to 85) | .49 |
| Male, No. (%) | 45 (91.8) | 42 (82.4) | 87 (87.0) | .24 |
| White, non-Hispanic, No. (%] | 47 (95.9) | 48 (94.1) | 95 (95.0) | 1.00 |
| Smoking history, No. (%) | ||||
| Current | 6(12.2) | 3 (5.9) | 9 (9.0) | .01 |
| Never | 36 (73.5) | 28 (54.9) | 64 (64.0) | |
| Former | 7 (14.3) | 20 (39.2) | 27 (27.0) | |
| Body mass index, No(%)‡ | ||||
| Normal (18.5–24.9 kg/m2) | 11 (23.4) | 8 (15.7) | 19 (19.4) | .67 |
| Overweight (25.0–29.9 kg/m2] | 20 (42.6) | 23 (45.1) | 43 (43.9) | |
| Obese (>30.0 kg/m2) | 16(34.0) | 20 (39.2) | 36 (36.7) | |
| ECOG performance | ||||
| No. fully active (%) | 45 (91.8) | 49(96.1) | 94 (94.0) | .43 |
| Concomitant medications§, No. (%) | ||||
| Proton pump inhibitors | 43 (87.8) | 48 (94.1) | 91 (91.0) | .31 |
| Histamine H2 receptor antagonists | 2 (4.1) | 3 (5.9) | 5 (5.0) | 1.00 |
| Aspirin | 15(30.6) | 18 (35.3) | 33 (33.0) | .67 |
| Grade of reflux esophagitis, No. (%) | ||||
| 0 | 48 (98.0) | 50 (98.0) | 98 (98.0) | 1.00 |
| ≥1 | 1 (2.0) | 1 (2.0) | 2 (2.0) | |
| Type of Barrett’s esophagus, No. (%) | ||||
| Circumferential | 37 (75.5) | 34 (66.7) | 71 (71.0) | .38 |
| Tongue | 29 (59.2) | 33 (64.7) | 62 (62.0) | .68 |
| Island | 20 (40.8) | 15 (29.4) | 35 (35.0) | .30 |
| Short segment | 6(12.2) | 10 (19.6) | 16 (16.0) | .42 |
| Median proximal level of | 32 (24 to 40) | 32 (22 to 42) | 32 (24 to 40) | .64 |
| Barrett’s esophagus, cm (IQR) | ||||
| Grade of dysplasia, No. (%) | ||||
| High | 19(38.8) | 17 (33.3) | 36 (36.0) | .68 |
| Low | 30(61.2) | 34 (66.7) | 64 (64.0) | |
| Helicobacter pylori status | ||||
| No. positive (%) | 1 (2.0) | 1 (2.0) | 2 (2.0) | 1.00 |
*
QR = interquartile range; ECOG = Eastern Cooperative Oncology Group.
†
P values were calculated with a two-sided Fisher’s exact test for categorical variables or a two-sided Wilcoxon rank sum test for continuous variables.
‡
Data were missing for two patients in the celecoxib group.
§
Proton pump inhibitors included were lansoprazole, omeprazole, rabeprazole, pantoprazole, and esomeprazole. Histamine H2 receptor antagonists were nizatidine, famotidine, cimetidine, and ranitidine.